Pharsight

Avycaz generic

Avycaz is an antibacterial drug owned by Allergan. It contains active ingredients Avibactam Sodium and Ceftazidime. It was first authorized for market use on 25 February, 2015.

When will Avycaz generic be available?

Avycaz has a total of 7 drug patents, none of which have expired so far. Drug patent challenges can be filed against Avycaz from 26 February, 2024. The generic versions of Avycaz are predicted to be released after 15 June, 2032.

Avycaz uses

Avycaz is extensively used for treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis. It is also prescribed for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). Its effectiveness is primarily due to the bactericidally effective amount of Avibactam Sodium.

Avycaz patent expiration

Avycaz holds 7 drug patents, with the latest set to expire on 2032-06-15. The patents primarily cover its active ingredients and methods of preparation. Pharmaceutical companies can file patent challenges against Avycaz from 2024-02-26. Avycaz generics are expected to enter the market after 2032-06-15. Below are the details of the patents:

EPO Oppostions filed on Avycaz

Avycaz dosage

Want to ask something?